BML Capital Sells Entire $5 Million Stake in Alumis, 250% Rally in Past Year
ByAinvest
Wednesday, Feb 4, 2026 5:57 pm ET1min read
ALMS--
BML Capital Management sold its entire 1.21 million-share stake in Alumis, a clinical-stage biotech, for $4.83 million in December 2022. The fund's decision to exit was likely due to Alumis' lack of approved products and high R&D spend. Alumis' shares have surged 255.1% over the past year, but the company's cash and marketable securities are still substantial at $377.7 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet